Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2026; 32(46): 122731
Published online Dec 14, 2026. doi: 10.3748/wjg.122731
Published online Dec 14, 2026. doi: 10.3748/wjg.122731
Helicobacter pylori in solid organ transplantation: Challenges and treatment strategies
Xiao-Han Fang, Division of Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Man Xie, Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266100, Shandong Province, China
Wei Rao, Organ Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao 266100, Shandong Province, China
Author contributions: Fang XH contributed to writing - original draft; Xie M and Rao W contributed to guidance.
AI contribution statement: This article did not utilize AI tools.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Wei Rao, Organ Transplantation Center, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao 266100, Shandong Province, China. qdfy_raowei@qdu.edu.cn
Received: May 6, 2026
Revised: July 30, 2026
Accepted: October 8, 2026
Published online: December 14, 2026
Processing time: 167 Days and 19.7 Hours
Revised: July 30, 2026
Accepted: October 8, 2026
Published online: December 14, 2026
Processing time: 167 Days and 19.7 Hours
Core Tip
Core Tip: Helicobacter pylori (H. pylori) prevalence among solid organ transplant recipients has decline substantially over the past several years, with contemporary estimates approximating 33%. Notably, pooled analysis suggests a reduced risk of H. pylori infection in transplant recipients compared with non-transplant populations, likely attributable to frequent perioperative antibiotic prophylaxis and routine proton-pump inhibitor use rather than altered susceptibility from immunosuppression. However, given the adverse consequence of H. pylori infection, periodic H. pylori screening and timely eradication with dose-adjusted immunosuppression represent a rational long-term surveillance strategy.